Durnham, North Carolina, June 27, 2011 – Vascular BioSciences announces the publication of a scientific article which describes the sequential hemodynamic, angiographic, and histologic characterization of an aortopulmonary shunt animal model of chronic pulmonary hypertension (PAH) by using an experimental endoarterial biopsy catheter in the current issue of Comparative Medicine.
The paper “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension” in the current issue of Comparative Medicne, Volume 61, Number 3, June 2011 , pp. 258-262(5) by Abraham Rothman, Robert G. Wiencek, Stephanie Davidson, William N Evans, Humberto Restrepo, Valeri Sarukhanov, Amanda Rivera-Begeman, and David Mann, describes the use of an experimental endoarterial biopsy catheter to describe the hemodynamic, angiographic, and histologic progression of a swine aortopulmonary shunt model of chronic pulmonary hypertension. The use of the endoarterial biopsy catheter allowed for sequential pulmonary vascular biopsy procedures as the PAH model developed. This PAH large animal model can be used to test therapeutic agents or interventions at several hemodynamic and disease stages, including at baseline prior to shunt surgery, during the initial high-flow but low-pressure state, and during the development of PAH.
The animal model described in this paper showed hemodynamic, angiographic, and histologic characteristics of chronic pulmonary arterial hypertension that mimicked the arterial pulmonary hypertension of systemic‒to‒pulmonary arterial shunts in humans. Experimental data obtained using this and other models and application of an in vivo endoarterial biopsy technique may aid in understanding mechanisms and developing therapies for experimental and human pulmonary arterial hypertension.
A unique aspect of this study was the use of an experimental endoarterial biopsy catheter to obtain several biopsy samples sufficient enough for tissue examination. The catheter was safe and effective in this model. Biopsy procedures were performed without complication and biopsy samples collected supported analysis of DNA, mRNA transcripts, and microRNAs. Use of the endoarterial biopsy catheter now adds the potential of sequential study of vascular tissue at different stages of PAH evolution and therapy. Genetic and structural endovascular changes can be tracked with biopsies in the course of a specific therapy. Application of this biopsy catheter may increase understanding and open new avenues for therapy in human PAH.
Comments Vascular BioSciences CEO David Mann, “This paper demonstrates the utility and safety of the endoarterial biopsy catheter in a large animal model of rapidly evolving PAH with similarities to types of PAH seen in patients. We have now successfully used the biopsy catheter to sample pulmonary arteries more than 1000 times preclinically, and we look forward to further application of our device.”
A link to this article can be found here: http://vascularbiosciences.com/wp-content/uploads/2013/11/Comparative-Medicine-paper-2011.pdf
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through it’s majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult to treat diseases.
For more information, please contact firstname.lastname@example.org